[1]
Liu Y, Liu S, Liu L, Gong X, Liu J, Sun L, Liu X, Wu L, Chen L, Wang L, Luo L, Lin J, Tie N, Jiang Z, Wu J, Lu F, Sun H, Li X, Yang N, Chai K, Wei H, Da Z, Zhao C, Dai L, Wang Y, Shi G, Zhang Z, Song H, Guo Q, Liu YC, Li Z. Fine Comparison of the Efficacy and Safety Between GB242 and Infliximab in Patients with Rheumatoid Arthritis: A Phase III Study. Rheumatology and therapy. 2022 Feb:9(1):175-189. doi: 10.1007/s40744-021-00396-8. Epub 2021 Nov 22
[PubMed PMID: 34806155]
[2]
Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet (London, England). 1999 Dec 4:354(9194):1932-9
[PubMed PMID: 10622295]
Level 1 (high-level) evidence
[3]
Lahad A, Weiss B. Current therapy of pediatric Crohn's disease. World journal of gastrointestinal pathophysiology. 2015 May 15:6(2):33-42. doi: 10.4291/wjgp.v6.i2.33. Epub
[PubMed PMID: 25977836]
[4]
Pola S, Patel D, Ramamoorthy S, McLemore E, Fahmy M, Rivera-Nieves J, Chang JT, Evans E, Docherty M, Talamini M, Sandborn WJ. Strategies for the care of adults hospitalized for active ulcerative colitis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2012 Dec:10(12):1315-1325.e4. doi: 10.1016/j.cgh.2012.07.006. Epub 2012 Jul 24
[PubMed PMID: 22835577]
[5]
Alpsoy E, Leccese P, Emmi G, Ohno S. Treatment of Behçet's Disease: An Algorithmic Multidisciplinary Approach. Frontiers in medicine. 2021:8():624795. doi: 10.3389/fmed.2021.624795. Epub 2021 Apr 28
[PubMed PMID: 33996847]
[6]
Baughman RP, Valeyre D, Korsten P, Mathioudakis AG, Wuyts WA, Wells A, Rottoli P, Nunes H, Lower EE, Judson MA, Israel-Biet D, Grutters JC, Drent M, Culver DA, Bonella F, Antoniou K, Martone F, Quadder B, Spitzer G, Nagavci B, Tonia T, Rigau D, Ouellette DR. ERS clinical practice guidelines on treatment of sarcoidosis. The European respiratory journal. 2021 Dec:58(6):. pii: 2004079. doi: 10.1183/13993003.04079-2020. Epub 2021 Dec 16
[PubMed PMID: 34140301]
Level 1 (high-level) evidence
[7]
Shih T, Lee K, Grogan T, De DR, Shi VY, Hsiao JL. Infliximab in hidradenitis suppurativa: A systematic review and meta-analysis. Dermatologic therapy. 2022 Sep:35(9):e15691. doi: 10.1111/dth.15691. Epub 2022 Jul 18
[PubMed PMID: 35790062]
Level 1 (high-level) evidence
[8]
Akiho H, Yokoyama A, Abe S, Nakazono Y, Murakami M, Otsuka Y, Fukawa K, Esaki M, Niina Y, Ogino H. Promising biological therapies for ulcerative colitis: A review of the literature. World journal of gastrointestinal pathophysiology. 2015 Nov 15:6(4):219-27. doi: 10.4291/wjgp.v6.i4.219. Epub
[PubMed PMID: 26600980]
[9]
You Y, Stelzl P, Joseph DN, Aldo PB, Maxwell AJ, Dekel N, Liao A, Whirledge S, Mor G. TNF-α Regulated Endometrial Stroma Secretome Promotes Trophoblast Invasion. Frontiers in immunology. 2021:12():737401. doi: 10.3389/fimmu.2021.737401. Epub 2021 Nov 1
[PubMed PMID: 34790194]
[10]
Ryman JT, Meibohm B. Pharmacokinetics of Monoclonal Antibodies. CPT: pharmacometrics & systems pharmacology. 2017 Sep:6(9):576-588. doi: 10.1002/psp4.12224. Epub 2017 Jul 29
[PubMed PMID: 28653357]
[11]
Scott FI, Lichtenstein GR. Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease. Current treatment options in gastroenterology. 2014 Mar:12(1):59-75. doi: 10.1007/s11938-013-0004-5. Epub
[PubMed PMID: 24452768]
[13]
Jiang Y, Lin O, Sinha SR. Use of Tumor Necrosis Factor Alpha Inhibitors for Inflammatory Bowel Disease Patients with Concurrent Heart Failure. Digestive diseases and sciences. 2017 Jun:62(6):1597-1606. doi: 10.1007/s10620-017-4574-2. Epub 2017 Apr 17
[PubMed PMID: 28417241]
[14]
Lichtenstein L, Ron Y, Kivity S, Ben-Horin S, Israeli E, Fraser GM, Dotan I, Chowers Y, Confino-Cohen R, Weiss B. Infliximab-Related Infusion Reactions: Systematic Review. Journal of Crohn's & colitis. 2015 Sep:9(9):806-15. doi: 10.1093/ecco-jcc/jjv096. Epub 2015 Jun 19
[PubMed PMID: 26092578]
Level 1 (high-level) evidence
[15]
Djokanovic N, Klieger-Grossmann C, Pupco A, Koren G. Safety of infliximab use during pregnancy. Reproductive toxicology (Elmsford, N.Y.). 2011 Jul:32(1):93-7. doi: 10.1016/j.reprotox.2011.05.009. Epub 2011 May 20
[PubMed PMID: 21621603]
[16]
Penagini F, Cococcioni L, Pozzi E, Dilillo D, Rendo G, Mantegazza C, Zuccotti GV. Biological therapy in pediatric age. Pharmacological research. 2020 Nov:161():105120. doi: 10.1016/j.phrs.2020.105120. Epub 2020 Aug 9
[PubMed PMID: 32783974]
[18]
Kelsen JR, Grossman AB, Pauly-Hubbard H, Gupta K, Baldassano RN, Mamula P. Infliximab therapy in pediatric patients 7 years of age and younger. Journal of pediatric gastroenterology and nutrition. 2014 Dec:59(6):758-62. doi: 10.1097/MPG.0000000000000533. Epub
[PubMed PMID: 25419596]
[19]
Li J, Zhang Z, Wu X, Zhou J, Meng D, Zhu P. Risk of Adverse Events After Anti-TNF Treatment for Inflammatory Rheumatological Disease. A Meta-Analysis. Frontiers in pharmacology. 2021:12():746396. doi: 10.3389/fphar.2021.746396. Epub 2021 Nov 1
[PubMed PMID: 34790122]
Level 1 (high-level) evidence
[20]
Dermawan A, So K, Venugopal K, Picardo S. Infliximab-induced optic neuritis. BMJ case reports. 2020 Dec 22:13(12):. doi: 10.1136/bcr-2020-236041. Epub 2020 Dec 22
[PubMed PMID: 33370961]
Level 3 (low-level) evidence
[21]
Mandarelli G, Iannone F, Ferracuti S, Grattagliano I, Benevento M, Solarino B, Ferorelli D, Catanesi R. Informed consent and biological agents in rheumatology and internal medicine. European journal of clinical investigation. 2022 Sep:52(9):e13805. doi: 10.1111/eci.13805. Epub 2022 May 18
[PubMed PMID: 35488744]
[22]
Agarwal A, Kedia S, Jain S, Gupta V, Bopanna S, Yadav DP, Goyal S, Mouli VP, Dhingra R, Makharia G, Ahuja V. High risk of tuberculosis during infliximab therapy despite tuberculosis screening in inflammatory bowel disease patients in India. Intestinal research. 2018 Oct:16(4):588-598. doi: 10.5217/ir.2018.00023. Epub 2018 Oct 10
[PubMed PMID: 30301331]
[23]
Ulutaş F, Korkmaz C, Yılmaz H, Akça D, Çomut E, Çelık M, Çobankara V. Intestinal Peripheral T-Cell Lymphoma in a Patient with Ankylosing Spondylitis Under Treatment with Infliximab: A Case Report and Review of the Literature. Mediterranean journal of rheumatology. 2022 Jun:33(2):247-251. doi: 10.31138/mjr.33.2.247. Epub 2022 Jun 30
[PubMed PMID: 36128217]
Level 3 (low-level) evidence
[24]
Shah ED, Coburn ES, Nayyar A, Lee KJ, Koliani-Pace JL, Siegel CA. Systematic review: hepatosplenic T-cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System. Alimentary pharmacology & therapeutics. 2020 Mar:51(5):527-533. doi: 10.1111/apt.15637. Epub 2020 Jan 28
[PubMed PMID: 31990422]
Level 1 (high-level) evidence
[25]
Lee CK. [Ideal vaccination strategy in inflammatory bowel disease]. The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi. 2015 Mar:65(3):159-64
[PubMed PMID: 25797379]
[26]
Choi DK, Rubin DT, Puangampai A, Lach M. Role and Impact of a Clinical Pharmacy Team at an Inflammatory Bowel Disease Center. Crohn's & colitis 360. 2023 Apr:5(2):otad018. doi: 10.1093/crocol/otad018. Epub 2023 Apr 15
[PubMed PMID: 37082614]